Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Revenue

Prestige BioPharma had revenue of 7.70B KRW in the quarter ending December 31, 2025, with 147.35% growth. This brings the company's revenue in the last twelve months to 19.02B, up 224.15% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.

• Revenue (ttm): 19.02B
• Revenue Growth: +224.15%
• P/S Ratio: 4.49
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 85.46B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	14.33B	13.64B	1,978.97%
Jun 30, 2024	689.08M	527.23M	325.77%
Jun 30, 2023	161.84M	-	-
Jun 30, 2022	-	-	-
Jun 30, 2021	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 26, 2026

Data Sources Report a data error